Insmed’s shares double as lung disease med powers past expectations in phase 3

Insmed’s medicine didn’t just reduce exacerbations of a chronic lung disease in a phase 3 trial. The drug blew the primary endpoint out of the water with “very statistically significant” results, according to analysts.